Buy Darzalex (daratumumab)
Price range: $395.00 through $1,185.00
Darzalex (daratumumab) is a human CD38-directed monoclonal antibody used to treat multiple myeloma
Who is Darzalex (daratumumab) for?
Darzalex (daratumumab) is indicated for patients with:
-
newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (first-line treatment). For this indication, it is used in combination with bortezomib, melphalan, and prednisone.
-
multiple myeloma who have received at least one prior therapy (second-line treatment). For this indication, it is used in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.
-
multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (third-line treatment). For this indication, it is used in combination with pomalidomide and dexamethasone.
-
multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent (fourth-line treatment). For this indication, it is used as monotherapy.
How does Darzalex (daratumumab) work?
Multiple myeloma is a form of blood cancer that occurs in infection-fighting plasma cells (a type of white blood cell) found in the bone marrow. These cancerous cells multiply, producing an abnormal protein and pushing out other healthy blood cells from the bone marrow.
Daratumumab is a monoclonal antibody that works by helping certain cells in the immune system attack these cancer cells. One of the antigens expressed on the surface of multiple myeloma cells is called CD38. Anti-CD38 antibodies, like daratumumab, target multiple myeloma cells by binding to the CD38 antigen and then signaling the patient’s immune system to attack the tumour.
Where has Darzalex (daratumumab) been approved?
Darzalex (daratumumab) was approved for multiple myeloma by:
- Food and Drug Administration (FDA), USA:
- May 7, 2018, as first-line therapy in combination with bortezomib, melphalan, and prednisone.
- November 21, 2016, as second-line therapy in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.
- June 16, 2017, as third-line therapy in combination with pomalidomide and dexamethasone.
- November 16, 2015, as fourth-line therapy.
- EMA (EU) on May 20, 2016.
- Health Canada on June 29, 2016.
- TGA (AUS) on July 17, 2017
- Medsafe on November 20, 2017.
How is Darzalex (daratumumab) taken?
The recommended dose is 16 mg/kg body weight according to the following schedule.
As monotherapy and in combination with lenalidomide and low-dose dexamethasone:
-
weekly infusions for week 1–8 (total of 8 infusions)
-
from week 9–24 every 2 weeks (total of 8 infusions)
-
from week 25 onwards until disease progression every four weeks.
In combination with bortezomib and dexamethasone:
-
weekly infusions for week 1–9 (total of 9 infusions)
-
from week 10–24 every 3 weeks (total of 5 infusions)
-
from week 25 onwards until disease progression every four weeks.
In combination with bortezomib, melphalan, and prednisone (6-week cycle regimen):
-
weekly infusions for week 1–6 (total of 6 infusions)
-
from week 7–54 every 3 weeks (total of 16 infusions)
-
from week 55 onwards until disease progression every four weeks
Complete information about daratumumab dosage and administration can be found in the resources section.
Note: Consult your treating doctor for personalised dosing.
Are there any known adverse reactions or side effects of Darzalex (daratumumab)?
Common adverse reactions
The most common side effects adverse reactions (incidence ≥20%) listed in the prescribing information include1:
- infusion reactions
- neutropenia (low white blood cells count)
- thrombocytopenia (low blood platelet count)
- fatigue (tiredness)
- nausea (feeling sick)
- diarrhea
- vomiting
- muscle spasms
- back pain
- pyrexia (fever)
- cough
- dyspnea (Shortness of breath)
- dizziness (feeling of being lightheaded, woozy, or unbalanced)
- insomnia
- peripheral edema (accumulation of fluids in the limbs)
- peripheral sensory neuropathy
- upper respiratory tract infection.
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:
- infusion reactions
- neutropenia
- thrombocytopenia.
| Quantity |
100mg / 5mL ,400mg / 20mL |
|---|
Shipping and delivery
All orders will only be dispatched once payment has been confirmed. Please fill in the shipping details and choose the payment method that suits you best.
-Shipping costs
You should always be clearly informed of the total price of your purchase, including delivery and other associated costs.
You must explicitly agree to any additional charges, for example if the merchant offers express delivery or gift wrapping.
-Damaged goods
The merchant is responsible for any damage caused to the product, from dispatch to receipt.
If you have purchased an item that does not conform in appearance or function to the advertised product, you have the right to request that it be repaired, replaced or, if neither of these is possible, refunded.
- Non-delivery
If you have not received the product within 30 days or by the agreed date, you must notify the merchant and allow a reasonable extension of time for delivery.
For example, if the merchant informs you of a one-week delay due to problems with his suppliers, it seems reasonable to allow him this extra week. If the trader still fails to deliver despite the extension, you have the right to terminate the contract and receive a prompt refund.
Related products
Buy Ibrance (palbociclib)
What is Ibrance (palbociclib) for?
Palbociclib is indicated for the treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer as initial endocrine-based therapy for their metastatic disease. It is indicated in combination with an aromatase inhibitor (an hormonal therapy) as initial endocrine based therapy in postmenopausal women or fulvestrant in women with disease progression following endocrine therapy.How does Ibrance (palbociclib) work?
Palbociclib is an inhibitor of cyclin-dependent kinase (CDK) 4 and 6.
Before a cell can divide, it has to go through four phases. The first phase is a growth phase (G1-phase), the second a synthesis phase (S-phase), the third another growth phase (G2-phase) and the last phase, where the cell divides (M-phase). Cancer cells divide exceedingly fast, passing through these 4 phases rapidly. Palbociclib blocks the progression from the first G1-phase, into the second S-phase. It does this by inhibiting the cyclin-dependent kinases 4 and 6 (CDK4 and CDK6)—two proteins that are involved in entering the S-phase[1].
Buy Kadcyla (Trastuzumab Emtansine)
Buy Keytruda (pembrolizumab)
Buy Opdivo (Nivolumab)
What is Opdivo (nivolumab) for?
Opdivo (nivolumab) is indicated for the treatment of patients with:- metastatic melanoma as a single agent or in combination with ipilimumab
- metastatic non-small cell lung cancer (NSCLC) whose cancer progressed on or after chemotherapy
- advanced renal cell carcinoma who have received prior anti-angiogenic therapy
- classical Hodgkin lymphoma that has relapsed or progressed after other treatments
- recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression on or within 6 months of receiving platinum-based chemotherapy
- locally advanced unresectable or metastatic urothelial carcinoma following progression on a platinum-containing therapy
- microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan
- hepatocellular carcinoma in patients who have been previously treated with sorafenib
- for the adjuvant treatment of completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease in patients who have received neoadjuvant chemoradiotherapy (CRT).
Buy Perjeta (Pertuzumab)
What is Perjeta (pertuzumab) for?
Perjeta (pertuzumab) is indicated for the treatment of HER2 positive breast cancer in patients with metastatic cancer or as neoadjuvant treatment for patients with locally advanced, inflammatory, or early stage breast cancer as part of a complete treatment regimen for early breast cancer
Buy Tecentriq (Atezolizumab)
Reviews
There are no reviews yet.